secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001213900-25-037654
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale
--------------------------------------------------------------------------------

- Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.
- ABVC has 45 days to submit a compliance plan; if accepted, it may have until Oct 21, 2025 to regain compliance.
- Sold 724,372 common shares to 15 non-U.S. persons for gross proceeds of ~$436,000 under Regulation S.
- Each purchaser agreed to transfer voting rights to Chairman Eugene Jiang via a Voting Rights Proxy Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/0001213900-25-037654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/ea0239740-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-037654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer